Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Genome Pharmaceuticals (Pvt.) Ltd,

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000454 149 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx149product presentations
G71generic molecules
DF6dosage-form groups
TA12therapeutic areas
PKR149current price records
REG145registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixGenome Pharmaceuticals (Pvt.) Ltd,Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/genome-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Anti-infectives65 · 44%CNS & mental health24 · 16%Gastrointestinal & hepatology16 · 11%Cardiovascular13 · 9%Oncology & immunology9 · 6%Vitamins, minerals & nutrition8 · 5%Hematology & thrombosis6 · 4%Other therapeutic areas8 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioGenome Pharmaceuticals (Pvt.) Ltd,Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/genome-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026149presentationsTablet93 · 62%Capsule39 · 26%Injection8 · 5%Suspension7 · 5%Pessary1 · 1%Syrup1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionGenome Pharmaceuticals (Pvt.) Ltd,Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/genome-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026137comparable productsBelow market median14 · 10%Near market median80 · 58%Above market median43 · 31%Company median price position+2.8%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsGenome Pharmaceuticals (Pvt.) Ltd,Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/genome-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026M/s. Genix Pharma (Pvt) Ltd.44 shared62% overlapCCL Pharmaceuticals (Pvt.) Ltd.40 shared56% overlapNeutro Pharma (Pvt.) Ltd.,40 shared56% overlapHigh-Q Pharmaceuticals39 shared55% overlapNabiqasim Industries (Pvt) Ltd.,37 shared52% overlapHilton Pharma (Pvt) Limited.36 shared51% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives65 products · 44%
CNS & mental health24 products · 16%
Gastrointestinal & hepatology16 products · 11%
Cardiovascular13 products · 9%
Oncology & immunology9 products · 6%
Vitamins, minerals & nutrition8 products · 5%
Hematology & thrombosis6 products · 4%
Dermatology4 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antimalarials11 products · 7%
Fluoroquinolone antibacterials11 products · 7%
Antipsychotics11 products · 7%
Antivirals10 products · 7%
Macrolide antibacterials9 products · 6%
Antiepileptics8 products · 5%
Antifungals8 products · 5%
Vitamins / minerals / hematinics8 products · 5%
Formulation footprint

Dosage forms

Tablet93 products
Capsule39 products
Injection8 products
Suspension7 products
Pessary1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ArefedDeferasirox 4presentations 180 mg, 250 mg, 360 mg, 500 mg · Tablet #2 MethoraxMethotrexate 4presentations 10 mg, 2.5 mg · Tablet #3 OnironOndansetron 4presentations 4 mg, 4 mg/2 mL, 8 mg, 8 mg/4 mL · Tablet, Injection #4 RepitantAprepitant 4presentations 125 mg, 40 mg, 80 mg · Capsule #5 BPRBisoprolol fumarate 3presentations 10 mg, 2.5 mg, 5 mg · Tablet #6 ButrinBupropion 3presentations 150 mg, 300 mg, 75 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1410% of comparable products
Near market median80within ±5% of median
Above market median4331% of comparable products
Lowest-price equivalents9ties included
Company median price position +2.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Intervirin 400 mgRibavirin · Capsule · 1 x 10's PKR 17.95/capsule-68.6% vs market median Thami 50 mgThalidomide · Capsule · 1x10's PKR 52.50/capsule-39.6% vs market median Lazer-250 250 mgLevofloxacin · Tablet · 1 x 10's PKR 29.92/tablet-37.0% vs market median Repol 2 mgLoperamide HCl · Capsule · 6 x 10's PKR 3.32/capsule-35.3% vs market median Meflogen 250 mgMefloquine · Tablet · 1 x 10's PKR 29.92/tablet-29.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 44shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 40shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 40shared generics High-Q Pharmaceuticals196 products · 59 generics 39shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 37shared generics Hilton Pharma (Pvt) Limited.262 products · 61 generics 36shared generics
Regulatory & price activity

Observed database signals

Registration numbers145
Price-history records153
Products with price history4
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

13 results
Intelligence filter: Therapeutic areaCardiovascular Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
BPR Bisoprolol fumarate 5 mg Tablet 2 x 10's 088009 PKR 249.31 PKR 12.47/tablet 7% above median
BPR Bisoprolol fumarate 10 mg Tablet 2 x 10's 088011 PKR 448.76 PKR 22.44/tablet Near median
BPR Bisoprolol fumarate 2.5 mg Tablet 1 x 14's 088010 PKR 59.84 PKR 4.27/tablet Near median
Losert Losartan 25 mg Tablet 2 x 10's 046471 PKR 231.29 PKR 11.56/tablet Near median
Losert Losartan 50 mg Tablet 2 x 10's 046469 PKR 420.53 PKR 21.03/tablet Near median
Mested Telmisartan + Hydrochlorothiazide 40 mg + 12.50 mg Tablet 14's 101415 PKR 572.44 PKR 40.89/tablet No comparator
Mested Plus-40 Telmisartan + Amlodipine 40 mg + 5 mg Tablet 14's 107424 PKR 712.51 PKR 50.89/tablet Near median
Mested Plus-80 Telmisartan + Amlodipine 80 mg + 5 mg Tablet 20's 107423 PKR 1,363.10 PKR 68.16/tablet Near median
Mested Plus-80 Telmisartan + Amlodipine 80 mg + 10 mg Tablet 14's 107422 PKR 1,187.53 PKR 84.82/tablet Near median
Nitrazim-2.6mg Nitroglycerin 2.6 mg Tablet 30's 108576 PKR 278.45 PKR 9.28/tablet Near median
Nitrazim-6.4mg Nitroglycerin 6.4 mg Tablet 30's 107536 PKR 383.06 PKR 12.77/tablet Near median
Provasc Amlodipine 5 mg Tablet 2 x 10's 079363 PKR 209.42 PKR 10.47/tablet Near median
Provasc Amlodipine 10 mg Tablet 2 x 10's 042522 PKR 396.91 PKR 19.85/tablet 14% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.